ARTICLES

When looking at the challenges facing the CEOs of emerging life science companies, it is useful to compare them with those confronting their  counterparts in emerging information technology companies. This is relevant for a number of reasons. Both are dependent on venture capital investment; both apply relatively young technology; and both are generally aiming at global, rather than local markets.

Download article